{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T03:27:59Z","timestamp":1782876479383,"version":"3.54.5"},"reference-count":30,"publisher":"AVES YAYINCILIK A.\u015e.","issue":"3","license":[{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Archives of Rheumatology"],"abstract":"<jats:p>Objectives: Considering that the comorbid situations during the management of Spondyloarthritis (SpA) have been underlined in several recommendations, the main objective of this study was to evaluate the comorbid conditions of Turkish patients with SpA.\r\nPatients and methods: This cross-sectional observational study was conducted with 1,242 SpA patients (844 males, 398 females; mean age: 43.9\u00b111.0 years; range, 19 to 81 years) diagnosed according to the modified New York criteria for ankylosing spondylitis or the Assessment of SpondyloArthritis International Society (ASAS) criteria. The patient data were collected from the Biologic and targeted Synthetic antirheumatic drugs Registry (BioStar) between February 1, 2019, and December 29, 2020. Clinical and demographic data, including, age, sex, disease duration, body mass index (BMI), pain, patient\u2019s global assessment, physician\u2019s global assessment, Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity Score, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Metrology Index, and Maastricht Enthesitis Score, were recorded. Comorbid conditions were recorded by filling out a questionnaire according to the clinical history or medical records. Charlson Comorbidity Index and Rheumatic Disease Comorbidity Index scores were calculated from the gathered comorbidity information.\r\nResults: Nine hundred thirteen patients had radiographic axial SpA, 153 had nonradiographic axial SpA, and 176 had peripheral SpA. The most common comorbidities were hypertension (HT) (n=167, 13.4%), diabetes mellitus (DM) (n=83, 6.7%), thyroid disorders (n=64, 5.6%), and depression (n=61, 4.9%). The comorbidities and the calculated comorbidity indices were significantly higher in females, in those with a BMI &gt;25 kg\/m2 , and those over 60 years of age. No relationship was found between smoking and alcohol use and comorbidities. A significantly higher prevalence of HT and DM in peripheral SpA patients and a lower prevalence of thyroid disorders in radiographic axial SpA patients were observed.\r\nConclusion: The most commonly reported comorbidities were HT, DM, thyroid disorders, and depression in SpA patients according to the BioStar database. The frequency of comorbidities and composite comorbidity scores were higher among females, older (&gt;60 years) patients, and overweight (BMI &gt;25 kg\/m2 ) patients.<\/jats:p>","DOI":"10.46497\/archrheumatol.2023.9793","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T10:02:36Z","timestamp":1707213756000},"page":"333-346","source":"Crossref","is-referenced-by-count":10,"title":["Real-life data on the comorbidities in spondyloarthritis from our multicenter nationwide registry: BioStar"],"prefix":"10.5152","volume":"38","author":[{"family":"H. Fatih \u00c7ay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Meltem Alkan Meliko\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Fatma G\u00fcl Yurdakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Hatice Bodur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"\u015eebnem Ataman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Erhan \u00c7apk\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"G\u00fclcan G\u00fcrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"\u0130lhan Sezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"M. Tuncay Duru\u00f6z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Aylin Rezvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"\u0130lker Ya\u011fc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Feride G\u00f6\u011f\u00fc\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ayhan Kamanli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Remzi \u00c7evik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"\u00d6zg\u00fcr Akg\u00fcl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3111","published-online":{"date-parts":[[2023,9,30]]},"reference":[{"key":"ref-1","doi-asserted-by":"crossref","unstructured":"Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: A guide to assess spondyloarthritis. Ann Rheum Dis 2009;68 Suppl 2:ii1-44.","DOI":"10.1136\/ard.2008.104018"},{"key":"ref-2","unstructured":"Status HD. Comorbidities What does \u201ccomorbidity\u201d mean ? 2020. Available at: https:\/\/www.cdc.gov\/ arthritis\/data_statistics\/comorbidities.htm"},{"key":"ref-3","doi-asserted-by":"crossref","unstructured":"Molt\u00f3 A, Dougados M. Comorbidities in spondyloarthritis including psoriatic arthritis. Best Pract Res Clin Rheumatol 2018;32:390-400.","DOI":"10.1016\/j.berh.2018.09.002"},{"key":"ref-4","doi-asserted-by":"crossref","unstructured":"Lee JS, Oh BL, Lee HY, Song YW, Lee EY. Comorbidity, disability, and healthcare expenditure of ankylosing spondylitis in Korea: A population-based study. PLoS One 2018;13:e0192524.","DOI":"10.1371\/journal.pone.0192524"},{"key":"ref-5","doi-asserted-by":"crossref","unstructured":"Molt\u00f3 A, Etcheto A, van der Heijde D, Landew\u00e9 R, van den Bosch F, Bautista Molano W, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: Results of the international crosssectional ASAS-COMOSPA study. Ann Rheum Dis 2016;75:1016-23.","DOI":"10.1136\/annrheumdis-2015-208174"},{"key":"ref-6","doi-asserted-by":"crossref","unstructured":"Bautista-Molano W, Landew\u00e9 R, Burgos-Vargas R, Maldonado-Cocco J, Molt\u00f3 A, van den Bosch F, et al. Prevalence of comorbidities and risk factors for comorbidities in patients with spondyloarthritis in Latin America: A comparative study with the general population and data from the ASAS-COMOSPA study. J Rheumatol 2018;45:206-12.","DOI":"10.3899\/jrheum.170520"},{"key":"ref-7","doi-asserted-by":"crossref","unstructured":"Jiang Y, Zhang P, Tu L, Lv Q, Qi J, Lin Z, et al. Prevalence of comorbidities and evaluation of screening in Chinese patients with spondyloarthritis. Clin Rheumatol 2018;37:423-8.","DOI":"10.1007\/s10067-017-3905-1"},{"key":"ref-8","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Medina C, Jim\u00e9nez-G\u00f3mez Y, Molt\u00f3 A, Schiotis RE, Marzo-Ortega H, van Gaalen FA, et al. Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: An ancillary study of the ASAS-COMOSPA project. Joint Bone Spine 2018;85:447-53.","DOI":"10.1016\/j.jbspin.2017.07.006"},{"key":"ref-9","doi-asserted-by":"crossref","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76:978-91.","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"ref-10","doi-asserted-by":"crossref","unstructured":"Bodur H, Yurdakul FG, Ataman \u015e, Garip Y, Nas K, Ayhan FF, et al. Turkish League Against Rheumatism consensus report: Recommendations for management of axial spondyloarthritis. Arch Rheumatol 2018;33:1-16.","DOI":"10.5606\/ArchRheumatol.2018.6833"},{"key":"ref-11","unstructured":"Molt\u00f3 A, Dougados M. Comorbidity indices. Clin Exp Rheumatol 2014;32(5 Suppl 85):S131-4."},{"key":"ref-12","doi-asserted-by":"crossref","unstructured":"England BR, Sayles H, Mikuls TR, Johnson DS, Michaud K. Validation of the rheumatic disease comorbidity index. Arthritis Care Res (Hoboken) 2015;67:865-72.","DOI":"10.1002\/acr.22456"},{"key":"ref-13","doi-asserted-by":"crossref","unstructured":"Huang YQ, Gou R, Diao YS, Yin QH, Fan WX, Liang YP, et al. Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy. J Zhejiang Univ Sci B 2014;15:58-66.","DOI":"10.1631\/jzus.B1300109"},{"key":"ref-14","doi-asserted-by":"crossref","unstructured":"Huang YJ, Chen JS, Luo SF, Kuo CF. Comparison of indexes to measure comorbidity burden and predict all-cause mortality in rheumatoid arthritis. J Clin Med 2021;10:5460.","DOI":"10.3390\/jcm10225460"},{"key":"ref-15","doi-asserted-by":"crossref","unstructured":"Zhao SS, Radner H, Siebert S, Duffield SJ, Thong D, Hughes DM, et al. Comorbidity burden in axial spondyloarthritis: A cluster analysis. Rheumatology (Oxford) 2019;58:1746-54.","DOI":"10.1093\/rheumatology\/kez119"},{"key":"ref-16","doi-asserted-by":"crossref","unstructured":"Redeker I, Callhoff J, Hoffmann F, Marschall U, Haibel H, Sieper J, et al. The prevalence and impact of comorbidities on patients with axial spondyloarthritis: Results from a nationwide population-based study. Arthritis Res Ther 2020;22:210.","DOI":"10.1186\/s13075-020-02301-0"},{"key":"ref-17","doi-asserted-by":"crossref","unstructured":"Chen HH, Yeh SY, Chen HY, Lin CL, Sung FC, Kao CH. Ankylosing spondylitis and other inflammatory spondyloarthritis increase the risk of developing type 2 diabetes in an Asian population. Rheumatol Int 2014;34:265-70.","DOI":"10.1007\/s00296-013-2927-5"},{"key":"ref-18","doi-asserted-by":"crossref","unstructured":"Derakhshan MH, Goodson NJ, Packham JC, Sengupta R, Molto A, Marzo-Ortega H, et al. Increased risk of hypertension associated with spondyloarthritis disease duration: Results from the ASAS-COMOSPA study. J Rheumatol 2019;46:701-9.","DOI":"10.3899\/jrheum.180538"},{"key":"ref-19","doi-asserted-by":"crossref","unstructured":"Genre F, Rueda-Gotor J, Quevedo-Abeledo JC, Corrales A, Hern\u00e1ndez-Hern\u00e1ndez V, Fa\u00f1anasRodr\u00edguez N, et al. Insulin resistance in non-diabetes patients with spondyloarthritis. Scand J Rheumatol 2020;49:476-83.","DOI":"10.1080\/03009742.2020.1751272"},{"key":"ref-20","doi-asserted-by":"crossref","unstructured":"Molt\u00f3 A, Nikiphorou E. Comorbidities in spondyloarthritis. Front Med (Lausanne) 2018;5:62.","DOI":"10.3389\/fmed.2018.00062"},{"key":"ref-21","doi-asserted-by":"crossref","unstructured":"Emmungil H, Erdogan M, Kalfa M, Karabulut G, Kocanaogullar\u0131 H, Inal V, et al. Autoimmune thyroid disease in ankylosing spondylitis. Clin Rheumatol 2014;33:955-61.","DOI":"10.1007\/s10067-013-2466-1"},{"key":"ref-22","doi-asserted-by":"crossref","unstructured":"Terlemez R, Akg\u00fcn K, Palamar D, Boz S, Sar\u0131 H. The clinical importance of the thyroid nodules during antitumor necrosis factor therapy in patients with axial spondyloarthritis. Clin Rheumatol 2017;36:1071-6.","DOI":"10.1007\/s10067-017-3607-8"},{"key":"ref-23","unstructured":"Khaoula BA, Slouma M, Dhahri R, Metoui L, Gharsallah I, Louzir B. Thyroid disorder in patients with spondylarthritis. Endocrine Abstracts 2020;70:EP528."},{"key":"ref-24","doi-asserted-by":"crossref","unstructured":"Fukui S, Ikeda Y, Kataoka Y, Yanaoka H, Tamaki H, Tsuda T, et al. Clinical significance of monitoring hypothyroidism in patients with autoimmune rheumatic disease: A retrospective cohort study. Sci Rep 2021;11:13851.","DOI":"10.1038\/s41598-021-93300-x"},{"key":"ref-25","doi-asserted-by":"crossref","unstructured":"Walsh JA, Song X, Kim G, Park Y. Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set. J Pharm Health Serv Res 2018;9:115-21.","DOI":"10.1111\/jphs.12212"},{"key":"ref-26","doi-asserted-by":"crossref","unstructured":"Parkinson JT, Foley \u00c9M, Jadon DR, Khandaker GM. Depression in patients with spondyloarthritis: Prevalence, incidence, risk factors, mechanisms and management. Ther Adv Musculoskelet Dis 2020;12:1759720X20970028.","DOI":"10.1177\/1759720X20970028"},{"key":"ref-27","doi-asserted-by":"crossref","unstructured":"Garrido-Cumbrera M, G\u00e1lvez-Ruiz D, DelgadoDom\u00ednguez CJ, Poddubnyy D, Navarro-Comp\u00e1n V, Christen L, et al. Impact of axial spondyloarthritis on mental health in Europe: Results from the EMAS study. RMD Open 2021;7:e001769.","DOI":"10.1136\/rmdopen-2021-001769"},{"key":"ref-28","doi-asserted-by":"crossref","unstructured":"Redeker I, Hoffmann F, Callhoff J, Haibel H, Sieper J, Zink A, et al. Determinants of psychological wellbeing in axial spondyloarthritis: An analysis based on linked claims and patient-reported survey data. Ann Rheum Dis 2018;77:1017-24.","DOI":"10.1136\/annrheumdis-2017-212629"},{"key":"ref-29","doi-asserted-by":"crossref","unstructured":"Reddy KN, Sabu N, Pandey N, Raut A, Joag K, Patil P. Anxiety and depression among patients with axial spondyloarthritis. Eur J Rheumatol 2022;9:8-13.","DOI":"10.5152\/eurjrheum.2021.21022"},{"key":"ref-30","doi-asserted-by":"crossref","unstructured":"Maas F, Arends S, van der Veer E, Wink F, Efde M, Bootsma H, et al. Obesity is common in axial spondyloarthritis and is associated with poor clinical outcome. J Rheumatol 2016;43:383-7.","DOI":"10.3899\/jrheum.150648"}],"container-title":["Archives of Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/download\/1350\/2392","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/download\/1350\/2393","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/download\/1350\/2392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T09:02:57Z","timestamp":1761210177000},"score":1,"resource":{"primary":{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/view\/1350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,30]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9,30]]}},"URL":"https:\/\/doi.org\/10.46497\/archrheumatol.2023.9793","relation":{},"ISSN":["2618-6500"],"issn-type":[{"value":"2618-6500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,30]]}}}